Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, November 5, 2020
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
[ Thu, Nov 05th 2020
] - WOPRAI
Matthew Luchini Downgraded (BLUE) to Hold and Held Target at $56 on, Nov 5th, 2020
Matthew Luchini of BMO Capital, Downgraded "bluebird bio, Inc." (BLUE) to Hold and Held Target at $56 on, Nov 5th, 2020.
Matthew has made no other calls on BLUE in the last 4 months.
There are 2 other peers that have a rating on BLUE. Out of the 2 peers that are also analyzing BLUE, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $68 on, Monday, August 10th, 2020
This is the rating of the analyst that currently disagrees with Matthew
- Difei Yang of "Mizuho" Initiated at Strong Buy and Held Target at $123 on, Tuesday, October 20th, 2020
